User:Mr. Ibrahem/Satralizumab

Satralizumab, sold under the brand name Enspryng, is a medication used to treat neuromyelitis optica spectrum disorder (NMOSD) in those who have antibodies against aquaporin 4 (AQP4). It is given by injection under the skin.

Common side effects include the headache, joint pain, high blood lipids, pain at the site of injection, and low white blood cells. Other side effects may include infection, liver problems, allergic reactions, and activation of latent tuberculosis. It is a monoclonal antibody that blocks interleukin-6 (IL-6) and thus decreases antibiotics against AQP4.

Satralizumab was approved for medical use in the United States in 2020 and Europe in 2021. In the United States it costs about 15,300 USD per dose as of 2021. It is not available in the United Kingdom as of 2021.